Native and bioengineered extracellular vesicles for cardiovascular therapeutics.

Area of Science:

• Biomedical Engineering
• Cardiovascular Research
• Nanomedicine

Background:

• Extracellular vesicles (EVs) are natural particles with inherent properties for intercellular communication and drug delivery.
• EVs can bypass biological barriers and deliver bioactive cargo to target cells, making them relevant for disease treatment.
• The therapeutic applications of native and bioengineered EVs in cardiovascular diseases are underexplored.

Purpose of the Study:

• To review the endogenous properties of EVs that facilitate their role as natural delivery agents.
• To discuss how bioengineering can enhance EV stability, targeting, and therapeutic efficacy.
• To examine the therapeutic potential and clinical translation challenges of EVs for cardiovascular diseases.

Main Methods:

• Review of existing literature on extracellular vesicle biology and bioengineering.
• Analysis of EV properties relevant to drug delivery and disease treatment.
• Discussion of bioengineering strategies for modifying EVs.

Main Results:

• EVs possess natural characteristics suitable for molecular cargo delivery and overcoming biological barriers.
• Bioengineering can significantly improve EV stability, targeting efficiency, and payload delivery.
• Current research on therapeutic EVs for cardiovascular diseases is limited but shows significant promise.

Conclusions:

• EVs represent a promising platform for cardiovascular disease therapeutics, leveraging their natural delivery functions.
• Bioengineering offers avenues to optimize EVs for enhanced therapeutic outcomes and targeted delivery.
• Advancing the clinical translation of EVs requires innovative approaches and integrated knowledge of molecular delivery systems.